ContraVir Pharmaceuticals to Present at Virtual Investor Conference

ContraVir Pharmaceuticals to Present at Virtual Investor Conference

July 5, 2018
Live Webcast Scheduled for July 12, 2018, 10:00 AM ET, followed by Q&A

EDISON, N.J., July 5, 2018 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today that James Sapirstein, CEO, will give a live virtual presentation at on Thursday, July 12, 2018 at 10:00 AM ET to discuss recent corporate, business and clinical updates.

View investor presentations 24/7 at . (PRNewsFoto/OTC Markets Group Inc.)

Presentation Information
Date:Thursday, July 12, 2018
Time:10:00 AM ET

This will be a live, interactive online event where investors are invited to ask the Company questions in real-time – both in the presentation hall as well as in the Company's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register and run the online system check to save time and receive event updates. For more information visit

About ContraVir Pharmaceuticals 
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™, a nucleoside analog lipid prodrug of tenofovir (TFV), is designed to deliver higher hepatic intracellular concentrations of the active tenofovir species (tenofovir diphosphate) while reducing concentrations of tenofovir outside the liver, causing fewer off-target toxicities and side-effects. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a novel structure that increases its potency and selective index against HBV. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg). For more information visit

Since 2010,, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform. Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

Cision View original content with multimedia:

SOURCE ContraVir Pharmaceuticals, Inc.

ContraVir Pharmaceuticals, Inc., Sharen Pyatetskaya, Director of Investor Relations,, (732) 902-4028;, John Viglotti,, (212) 729 8350